+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2018

  • ID: 4620368
  • Drug Pipelines
  • 46 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Cadila Healthcare Ltd
  • Daiichi Sankyo Co Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • MORE
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2018

Summary:

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis.

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I and Preclinical stages are 1 and 9 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Infectious Disease which include indications Type 2 Diabetes, Diabetes and Hepatitis B.

The latest report Free Fatty Acid Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Cadila Healthcare Ltd
  • Daiichi Sankyo Co Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • MORE
Introduction

Report Coverage

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Overview

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development

Amgen Inc

Cadila Healthcare Ltd

Daiichi Sankyo Co Ltd

Hyundai Pharmaceutical Co Ltd

Johnson & Johnson

Merck & Co Inc

Takeda Pharmaceutical Co Ltd

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles

AM-1638 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-3189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-1558 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasiglifam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOB-047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-2305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TUG-770 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYDG-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Products

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Product Development Milestones

Featured News & Press Releases

Dec 26, 2013: Takeda Announces Termination of Fasiglifam Development

Sep 26, 2013: Takeda Presents Fasiglifam Phase III data at the 49th Annual Meeting of the European Association for the Study of Diabetes

May 16, 2013: Takeda Pharma Announces Presentation Of Phase III Clinical Trial Results Of Fasiglifam At 56th Annual Meeting Of Japan Diabetes Society

Aug 22, 2012: Takeda Launches Phase III Clinical Trial In Asia For TAK-875 To Treat Diabetes

Feb 27, 2012: Takeda Announces Publication Of Phase II Data Of TAK-875 In The Lancet, Demonstrates Improved Glycemic Control In Patients With Type 2 Diabetes

Oct 18, 2011: Takeda Initiates Phase III Clinical Trial Program In US, Latin America, And Europe For Investigational Type 2 Diabetes Therapy TAK-

Sep 12, 2011: Takeda's TAK-875 Enters Into Phase III Clinical Trials For Treatment Of Type 2 Diabetes In Japan

Jun 28, 2011: Takeda Presents Late Breaking Data Of TAK-875 At American Diabetes Association 71st Annual Scientific Sessions

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Amgen Inc, H2 2018

Pipeline by Cadila Healthcare Ltd, H2 2018

Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2018

Pipeline by Johnson & Johnson, H2 2018

Pipeline by Merck & Co Inc, H2 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • Cadila Healthcare Ltd
  • Daiichi Sankyo Co Ltd
  • Hyundai Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4620368
Adroll
adroll